Pfizer (PFE 0.77%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

CellCentric has secured a Series C raise of $120million to advance its drug inobrodib, a first-in-class oral cancer drug to ...

The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years. Advancements in genetic ...

The HHS leader has a different view of health and wellness, and that's teasing out some tantalizing opportunities for ...

As soon as the news broke of a major layoff at New Haven biopharma company Arvinas earlier this month, texts and emails were flying across Connecticut between pharma executives, industry boosters and ...

The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. Increased R&D investment.

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...